ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
Pre-market 07:05:00 am | |||
| 831.8 USD | -0.10% |
|
833.7 | +0.24% |
| 01:00am | Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | RE |
| Jun. 05 | Health Care Climbs on Obesity-Drug Bets - Health Care Roundup | DJ |
Financials (USD)
| Sales 2024 * | 42.98B | Sales 2025 * | 52.62B | Capitalization | 749B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B | Net income 2025 * | 16.55B | EV / Sales 2024 * | 17.8 x |
| Net Debt 2024 * | 18.07B | Net Debt 2025 * | 15B | EV / Sales 2025 * | 14.5 x |
| P/E ratio 2024 * |
62.2
x | P/E ratio 2025 * |
44.8
x | Employees | 43,000 |
| Yield 2024 * |
0.62% | Yield 2025 * |
0.72% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +0.34% | ||
| 1 week | +2.49% | ||
| Current month | +1.39% | ||
| 1 month | +13.17% | ||
| 3 months | +6.97% | ||
| 6 months | +41.42% | ||
| Current year | +42.69% |
1 week
811.10
838.45
1 month
750.53838.45
Current year
579.05838.45
1 year
432.34838.45
3 years
201.83838.45
5 years
101.36838.45
10 years
58.50838.45
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 17 M€ | +8.17% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 831.8 | -0.10% | 2,169,003 |
| 24-06-04 | 832.6 | +0.16% | 1,748,288 |
| 24-06-03 | 831.3 | +1.33% | 2,537,239 |
| 24-05-31 | 820.3 | +0.65% | 4,472,119 |
| 24-05-30 | 815.1 | +0.43% | 1,986,290 |
Delayed Quote Nyse, June 05, 2024 at 04:00 pm EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
831.8
USD
Average target price
852.5
USD
Spread / Average Target
+2.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +42.69% | 749B | |
| +39.06% | 605B | |
| -6.87% | 351B | |
| +18.74% | 328B | |
| +6.76% | 292B | |
| +18.77% | 248B | |
| -2.49% | 214B | |
| +11.10% | 216B | |
| +2.64% | 167B | |
| +6.72% | 165B |
- Stock Market
- Equities
- LLY Stock
